Vida Ventures Advisors, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed April 12, 2024), Vida Ventures Advisors, LLC reported 5 stock positions worth $180.0 million. Its top holding was Kyverna Therapeutics (KYTX) at 62.4% of the portfolio, followed by Centessa Pharmaceuticals (CNTA, 24.7%) and Dyne Therapeutics (DYN, 6.4%). Compared with Q4 2023, it opened 1 new position, sold out of 3 and reduced 1. The biggest buy was a new position in Kyverna Therapeutics (KYTX) and the biggest sale Dyne Therapeutics (DYN, shares −80%).
- Most Recent 13F
- Q3 2025
- Location
- BOSTON, MA
- CIK
- 0001831423
- Portfolio Value
- $180.0M (Q1 2024)
- SEC Filing
- 0000950123-24-003271 ↗ filed Apr 12, 2024
Holdings Value
Holdings 5 stocks · $180.0M
| KYTX Kyverna Therapeutics Inc. | 62.43% | 4,523,924 | $112.4M | New |
| CNTA Centessa Pharmaceuticals Ltd. | 24.68% | 3,931,818 | $44.4M | No change |
| DYN Dyne Therapeutics Inc. | 6.43% | 407,499 | $11.6M | Reduce -80.4% |
| ALLO Allogene Therapeutics Inc. | 4.47% | 1,798,163 | $8.0M | No change |
| KRON Kronos Bio Inc. | 2.00% | 2,765,314 | $3.6M | No change |
Portfolio Sells Q4 2023 → Q1 2024
| DYN Dyne Therapeutics Inc. | Reduce -80.4% | 6.43% | −26.42 |
| LIANY Lianbio-ADR | Sold out | 0.00% | −12.14 |
| KNTE Kinnate Biopharma Inc. | Sold out | 0.00% | −6.23 |
| IKENA ONCOLOGY INC | Sold out | 0.00% | −0.53 |
Portfolio Buys Q4 2023 → Q1 2024
| KYTX Kyverna Therapeutics Inc. | New | 62.43% | +62.43 |